RecruitingNot applicableEN original

The Vanguard Study: Testing a New Way to Screen for Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Osoby w wieku od 45 do 75 lat
  • Zgoda na pobranie próbek krwi do badań
  • Zgoda na dostęp do informacji z dokumentacji medycznej
  • Zrozumienie i możliwość wypełnienia formularzy w języku angielskim, hiszpańskim lub arabskim

✗ Disqualifies

  • Diagnoza raka (guza litego lub krwi) w ciągu ostatnich 5 lat
  • Obecnie trwająca diagnostyka w kierunku raka
  • Udział w innym badaniu dotyczącym testów lub technologii do wykrywania raka
  • Karmienie piersią, ciąża lub planowanie ciąży w ciągu najbliższego roku

Simplified criteria — AI translation

Trial details

Minimum age
45 Years
Maximum age
75 Years
Last updated (source)
July 1, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (38)

Kaiser Permanente-Division of Research

Pleasanton, United States

Keefe Memorial Hospital

Cheyenne Wells, United States

Kaiser Permanente-Franklin

Denver, United States

Poudre Valley Hospital

Fort Collins, United States

Cancer Care and Hematology-Fort Collins

Fort Collins, United States

UCHealth Greeley Hospital

Greeley, United States

Kaiser Permanente-Rock Creek

Lafayette, United States

Kaiser Permanente-Lone Tree

Lone Tree, United States

Medical Center of the Rockies

Loveland, United States

Kaiser Permanente Moanalua Medical Center

Honolulu, United States

Walter Reed National Military Medical Center

Bethesda, United States

Henry Ford Cancer Institute-Downriver

Brownstown, United States

Henry Ford Health Center - Brownstown

Brownstown, United States

Henry Ford Health Center - Chesterfield

Chesterfield, United States

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, United States

Henry Ford Medical Center-Fairlane

Dearborn, United States

Henry Ford Hospital

Detroit, United States

Henry Ford Medical Center - Detroit Northwest

Detroit, United States

Henry Ford Medical Center-Cottage

Grosse Pointe Farms, United States

Henry Ford Medical Center - Livonia

Livonia, United States

Henry Ford Medical Center-Columbus

Novi, United States

Henry Ford Medical Center - Plymouth

Plymouth, United States

Henry Ford Medical Center - Royal Oak

Royal Oak, United States

Henry Ford Medical Center

Sterling Heights, United States

Henry Ford Medical Center - Troy

Troy, United States

Henry Ford West Bloomfield Hospital

West Bloomfield, United States

Henry Ford Wyandotte Hospital

Wyandotte, United States

Saint Luke's Hospital of Kansas City

Kansas City, United States

Washington University School of Medicine

St Louis, United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, United States

University of Oklahoma Health Sciences Center

Oklahoma City, United States

Sentara Martha Jefferson Hospital

Charlottesville, United States

Inova Schar Cancer Institute

Fairfax, United States

Inova Fair Oaks Hospital

Fairfax, United States

Sentara Norfolk General Hospital

Norfolk, United States

VCU Massey Cancer Center at Stony Point

Richmond, United States

VCU Massey Comprehensive Cancer Center

Richmond, United States

VCU Community Memorial Health Center

South Hill, United States

Trial contact

Site Public Contact

Jeffrey Lee

PRINCIPAL_INVESTIGATOR

Linda S. Cook

PRINCIPAL_INVESTIGATOR

Debra P. Ritzwoller

PRINCIPAL_INVESTIGATOR

Site Public Contact

Site Public Contact

Stacey Honda

PRINCIPAL_INVESTIGATOR

Site Public Contact

Kristen Natale

PRINCIPAL_INVESTIGATOR

Christine Neslund-Dudas

PRINCIPAL_INVESTIGATOR

Site Public Contact

Site Public Contact

Site Public Contact

Site Public Contact

Timothy J. Pluard

PRINCIPAL_INVESTIGATOR

Aimee S. James

PRINCIPAL_INVESTIGATOR

Daniel S. Reuland

PRINCIPAL_INVESTIGATOR

Mark Doescher

PRINCIPAL_INVESTIGATOR

Site Public Contact

John M. Sayles

PRINCIPAL_INVESTIGATOR

Rebecca D. Kaltman

PRINCIPAL_INVESTIGATOR

Site Public Contact

Site Public Contact

Alexander H. Krist

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.